Tomasz RL

Language: Spanish
References: 20
Page: 168-176
PDF size: 77.83 Kb.

ABSTRACT

Objectives: The analysis of correlation of therapeutic efficiency of Paroxetine with demographic factors (sex, age, financial conditions, education, number of diseases, intensity of depression, actual emotional state, religious outlook on life and professional status).
Methods: The total number of 99 patients were chosen for the study. Patients were treated with Paroxetine due to a “major depression” syndrome. Data for the study were taken from the diseases history of the persons. Patients were observed for six weeks. Each patient was individually examined by the psychiatrist and was diagnosed according to 24 points Hamilton Depression Evaluation Scale, Beck Depression Self-Assessment Inventory, Montgomery-Asberg Scale and CGI Scale, which allowed for the evaluation of the effects of the treatment.
Results: Significantly good effects of the treatment of “major depression” were obtained for men with high education in whom light depression syndrome occurred not much more than three times in life. Very good results were observed in about 27% of active believer patients. Whereas such demographic factors like age of the patients, financial conditions, actual emotional state and professional status had only little impact on therapeutic effects of the depression.
Conclusions: It has turned out that only some demographic factors clearly correlate with the therapeutic effects of the depression. Best effects of the treatment with Paroxetine were obtained for men with high education in whom not many light depression syndrome occurred in life. Some other demographic factors clearly correlate with the effect of treatment of the depression with Sulpiride.

REFERENCES

1. Bourin M, Chue P, Guillon Y. Paroxetina: revision (Paroxetine: a review). CNS Drug Reviews 2001;7(1):25-47, Spring.

2. Gilmor ML, Owens MJ, Nemeroff CB. La inhibición de la recaptación de la noradrenalina en pacientes con depresión mayor tratados con paroxetina (Inhibition of norepinephrine update in patients with major depression treated with paroxetine). American Journal of Psychiatry 2002;159(10):1702-10.

3. Bourin M. El uso de paroxetina en el tratamiento de depresión y trastornos de ansiedad en personas ancianas: revisión (Use of paroxetine for the treatment of depression and anxiety disorders in the elderly: a review). Human Psychopharmacology 2003;18(3):185-90.

4. Miller M. Depresión después del trasplante del corazón tratada con psicoterapia interpersonal y paroxetina (Depression after cariad transplant treated with interpersonal psychotherapy and paroxetine). American Journal of Psychotherapy 2002;56(4):555-61.

5. Autores anónimos. Paroxetina: nueva indicación. En la fobia social: evaluación mínima (Paroxetine: new indication. In social phobia: minimal assessment). Prescrive International 2003;12(66):137-9.

6. Randall CL, Johnson MR, Thevos AK, Sonne SC, Thomas SE, Willard SL, Brady KT, Davidson JR. Paroxetina en la fobia social y etilismo en pacientes con diagnóstico doble (Paroxetine for social anxiety and alcohol use in dual-diagnosed patients). Depression and Anxiety 2001;14(4): 255-62.

7. Grant JE, Kim SW, Protenza MN, Blanco C, Ibanez A, Stevens L, Hektner JM, Zaninelli R. Tratamiento con paroxetina de la adicción patológica a los juegos de azar: estudio/ensayo multicéntrico controlado randomizado (Paroxetine treatment of pathological gambling: amulti-centre randomized controlled trial). International Clinical Psychopharmacology 2003;18(4):243-9.

8. Creed F, Fernandes L, Guthrie E. Relación coste- eficacia de psicoterapia y paroxetina en el síndrome agudo del intestino grueso irritable (The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. Gastroenterology 2003;124(2):303-17.

9. Masand PS, Gupta S, Schwartz TL, Kaplan D. ¿Si los trastornos de ansiedad preexistentes predicen la respuesta a paroxetina en el síndrome del intestino grueso irritable? (Does a preexisting anxiety disorder predict response to paroxetine in irritable bowel syndrome?) Psychosomatics 2002;43(6):451-5.

10. Stearns V, Beebe KL, Iyengar M, Dube E. Paroxetina de liberación controlada en el tratamiento de sofocos de la menopausia: un ensayo controlado randomizado (Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial). JAMA 2003;289(21):2827-34.

11. Green B. Focalización en paroxetina (Focus on paroxetine). Current Medical Research and Opinion 2003;19(1):13-21.

12. DeVane CL. Interacciones farmacocinéticas de medicamentos y tolerabilidad de paroxetina y paroxetina de liberación controlada (CR). (Pharmacokinetics, drug interaction, and tolerability of paroxetine and paroxetine CR). Psychopharmacology Bulletin 2003;37(Suppl 1):29-41, Spring.

13. Arnone D, Hansen L, Kerr JS. Reacción distónica aguda en paciente de edad avanzada con trastornos del estado de ánimo en reacción a un aumento de la dosis de paroxetina: posibles mecanismos e implicaciones para terapia clínica (Acute dystonic reaction in an elderly patient with nood disorder after titration of paroxetine: possible mechanisms and implications for clinical care). Journal of Psychopharmacology 2002;16(4):395-7.

14. Azaz-Liwshits T, Hershko A, Ben-Chetrit E. Hepatotoxicidad asociada a paroxetina: reporte de 3 casos y revisión de la literatura (Paroxetine associated hepatotoxicity: a report of 3 cases and a review of the literature). Pharmacopsychiatry 2002;35(3):112-5.

15. Odeh M, Misselevech J, Boss JH, Oliven A. Hepatotoxicidad severa con hepatitis asociada a paroxetina (Severe hepatotoxicity with jaundice associated with paroxetine). American Journal of Gastroenterology 2001;96(8):2494-6.

16. Nickel T, Sonntag A, Schill J. Efectos clínicos y neurobiológicos de tianeptina y paroxetina en depresión mayor (Clinical and neurobiological effects of tianeptine and paroxetine in major depression). Journal of Clinical Psychopharmacology 2003;23(2):155-68.

17. Nebes Rd, Pollock BG Houck PR. Persistencia de disfunciones cognitivas en pacientes geriátricos después del tratamiento antidepresivo: estudio clínico randomizado doble ciego con nortriptilina y paroxetina (Persistence of cognitive impairment in geriatric patients following antidepressant treatment: a randomized, double-blind clinical trial with nortriptyline and paroxetine). Journal of Psychiatric Research 2003;37(2):99-108.

18. Bourin M, Chue P, Guillon Y. Paroxetina: revisión (Paroxetine: a review). CNS Drug Reviews 2001;7(1):25-47, Spring.

19. Dunner D, Kumar R. Paroxetina: revisión de experiencias clínicas (Paroxetine: a review of clinical experience). Pharmacopsychiatry 1998;31(3):89-101.

20. Weihs KL, Settle EC Jr, Batey SR. Bupropion de liberación sostenida en comparación con paroxetina en el tratamiento de depresión en personas en edad avanzada (Bupropion sustained release versus paroxetine for the treatment of depression in the elderly). Comentario en: J Clin Psychiatry. 2001 May: 62(5): 373-5, PM/D: 11411822. Journal of Clinical Psychiatry 2000;61(3):196-202.